AbbVie (NYSE:ABBV), a prominent biopharmaceutical company, is deeply involved in the research, development, manufacturing, commercialization, and distribution of medicines and therapies on a global scale. As the company gears up to announce its Q1 2025 earnings on April 25, before the market opens, investors and analysts are eagerly awaiting the results. Expectations from Wall Street analysts suggest that AbbVie will report an EPS of $2.51, a notable increase from the $2.31 reported in the same period last year. Furthermore, quarterly revenue is anticipated to reach $12.91 billion, up from $12.31 billion in the previous year.
AbbVie’s stock price has seen a 52-week range between $153.58 and $218.66. With a dividend yield of 3.86%, the company has paid out $6.56 per share in dividends over the last 12 months. In its recent Q4 2024 earnings report, AbbVie exceeded expectations, posting an adjusted EPS of $2.16, surpassing the street view of $2.11. The quarterly sales figures of $15.102 billion also outpaced the analyst consensus estimate of $14.827 billion.
Looking ahead, AbbVie has projected its full-year 2025 adjusted EPS to fall within the range of $12.12 to $12.32, slightly below the street view of $12.18. The company has reiterated its commitment to achieving a high single-digit compound annual revenue growth rate through 2029. For a comprehensive analysis of AbbVie, 13 analysts’ insights can be found in an article by Benzinga.
For income-focused investors looking to generate a steady income of $100 per month from AbbVie dividends, an investment value of approximately $31,088 is needed, which translates to around 183 shares at a price of $170.16 each. Calculating the dividend yield involves dividing the annual dividend payments by the current stock price. It’s important to note that the dividend yield can fluctuate based on changes in stock prices and dividend payments over time.
In conclusion, AbbVie stock presents an attractive option for investors seeking a consistent income stream. By owning 183 shares of the stock, investors can potentially earn $100 per month. As the company continues to make strides in the biopharmaceutical industry, AbbVie remains a compelling choice for those looking to build a reliable investment portfolio.
This article was originally published on Benzinga.com and offers valuable insights for investors interested in maximizing their returns through AbbVie stock. As always, it’s essential to conduct thorough research and seek professional advice before making any investment decisions.
